Causal effects between atrial fibrillation and heart failure: evidence from a bidirectional Mendelian randomization

Zhuxin Zhang1, Le Li1, Zhao Hu1

  • 1Fuwai Hospital, National Center for Cardiovascular Diseases, National Key Laboratory, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

BMC Medical Genomics
|August 14, 2023
PubMed

Insights

Atrial fibrillation (AF) and heart failure (HF) have a reciprocal causal relationship. Genetic predisposition to AF increases HF risk, and genetically determined HF elevates AF risk, supporting bidirectional causality.

Area of Science:

  • Cardiovascular Genetics
  • Epidemiology
  • Translational Medicine

Background:

  • Observational studies indicate a strong association between atrial fibrillation (AF) and heart failure (HF).
  • The causal relationship between AF and HF remains uncertain, necessitating further investigation.
  • Genetic factors may play a significant role in the interplay between AF and HF.

Purpose of the Study:

  • To investigate the causal effect of atrial fibrillation on heart failure.
  • To examine the causal effect of heart failure on atrial fibrillation.
  • To establish a bidirectional causal relationship between AF and HF using genetic data.

Main Methods:

  • Bidirectional Mendelian randomization (MR) analysis was employed.
  • Genetic instrumental variables were derived from large-scale genome-wide association studies for AF (n=1,030,836) and HF (n=1,665,481).
  • Inverse-variance weighted (IVW) was the primary estimation method, with MR-PRESSO, MR-Egger, and weighted median analyses used for sensitivity and pleiotropy assessment.

Main Results:

  • A genetically elevated predisposition to atrial fibrillation was associated with an increased risk of heart failure (OR=1.18, 95% CI: 1.14-1.22).
  • Genetically determined heart failure was associated with an increased risk of atrial fibrillation (OR=1.44, 95% CI: 1.23-1.68).
  • MR sensitivity analyses confirmed the robustness of these findings, indicating a consistent bidirectional causal link.

Conclusions:

  • This bidirectional Mendelian randomization study supports a reciprocal causal relationship between AF and HF.
  • The shared genetic architecture of AF and HF offers potential therapeutic targets for disease prevention and management.
  • Further research into molecular mechanisms and personalized genetic profiling is warranted for effective treatment strategies.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13